Original Article

Analysis of cyclin E co-expression genes reveals nuclear transcription factor Y subunit alpha is an oncogene in gastric cancer

Liang-Yu Bie a, Dan Li b, Yu Mu a, Sheng Wang c, Bei-Bei Chen a, Hui-Fang Lyu a, Li-Li Han a, Cai-Yun Nie a, Chang-Cheng Yang a, Lin Wang d, Chuan-Chuan Ren e, Wei-Jie Zhang f, Ping Guo g, Feng Shi h, Qing-Xia Fan f, Liu-Xing Wang f, Xiao-Bing Chen a,* Su-Xia Luo a,**

a Department of Oncology, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan 450008, China
b Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan 450008, China
c Department of Combined Traditional Chinese and Western Medicine Oncology, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan 450008, China
d Department of Radiation Oncology, Zhengzhou People’s Hospital, Zhengzhou, Henan 450008, China
e Department of Urology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China
f Department of Medical Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China
g Department of Oncology, The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan 473000, China
h Department of Thoracic Surgery, The First Affiliated Hospital of Nanyang Medical College, Nanyang, Henan 473000, China

Received 23 November 2017
Available online 23 October 2018

Abstract

Objective: To explore genes potentially co-expressed with cyclin E in gastric cancer and discover possible targets for gastric cancer treatment.

Methods: The Cancer Genome Atlas (TCGA) stomach adenocarcinoma sequencing data were used to predict genes co-expressed with cyclin E. Co-expression genes predicted by cBioPortal online analysis with Pearson correlation coefficient ≥0.4 were analyzed by gene ontology (GO) enrichment annotation using the PANTHER online platform (Ver. 7). Interactions between proteins encoded by these genes were analyzed using the STRING online platform (Ver. 10.5) and Cytoscape software (Ver. 3.5.1). Genes displaying a high degree of connection were analyzed by transcription factor enrichment prediction using FunRich software (Ver. 3). The significant transcription factor and cyclin E expression levels and their impact on gastric cancer progression were analyzed by Western blotting and Kaplan–Meier survival curve analysis.

Results: After filtering the co-expression gene prediction results, 78 predicted genes that included 73 protein coding genes and 5 non-coding genes with Pearson correlation coefficient ≥0.4 were selected. The expressions of the genes were considered to
be correlated with cyclin E expression. Among the 78 genes co-expressed with cyclin E, 19 genes at the central of the regulatory network associated with cyclin E were discovered. Nuclear transcription factor Y subunit alpha (NF-YA) was identified as a significant transcription factor associated with cyclin E co-expressing genes. Analysis of specimen donors’ clinical records revealed that high expression of NF-YA tended to be associated with increased cyclin E expression. The expression of both was associated with progression of gastric cancer. Western blotting results showed that compared with normal tissues, NF-YA and cyclin E were highly expressed in tumor tissues \( (P < 0.001) \). Survival curve analysis clearly demonstrated relatively poor overall survival of gastric cancer patients with high cyclin E or high NF-YA expression level, compared to patients with low cyclin E or NF-YA expression \( (P < 0.05) \).

**Conclusions:** NF-YA may promote gastric cancer progression by increasing the transcription of cyclin E and other cell cycle regulatory genes. NF-YA might be a potential therapeutically useful prognostic factor for gastric cancer.

© 2018 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**Keywords:** Cyclin E; Nuclear transcription factor Y subunit alpha; Oncogene; Gastric cancer

---

**Introduction**

The incidence of gastric cancer is increasing in developing countries. This imposes a significant financial burden for patients and the healthcare system. Surgical treatment, chemotherapy, and targeted-therapy have been employed in gastric cancer treatment, but the treatment outcome and patients’ post-treatment survival remain disappointing, especially for patients with late stage carcinoma. Cancer cells are characterized by uncontrolled hyper-proliferation. Targeting the cell proliferation machinery or the signal transduction network promoting cell proliferation has been proposed as possible therapeutic options for cancer management. Regulation of the cell cycle is frequently altered in cancer by different genetic and epigenetic causes, and the de-regulated cell cycle progression is crucial in cell proliferation and cancer development, in which cyclins and cyclin dependent kinases are direct promoters. Targeting the cell cycle has been accepted in-principle as a potential therapeutic option. However, the molecular mechanisms of altered cell cycle machineries that promote gastric cancer progression remain unclear.

Gene amplification and overexpression of cyclin E have been recently linked to gastric cancer development and poor prognosis. During the progression of the cell cycle, cyclin E binds to and activates cyclin-dependent kinase 2, which promotes G1/S entry by phosphorylating the appropriate substrates. Cyclin E overexpression has been reported in gastric cancer, but the molecular mechanism of the up-regulation remains unclear. In this study, we aimed to discover possible mechanisms that may be involved in regulating cyclin E expression by identifying and investigating genes that are potentially co-expressed with cyclin E in gastric cancer. This was done by querying The Cancer Genome Atlas (TCGA) stomach adenocarcinoma sequencing data with different bioinformatics approaches.

**Materials and methods**

**Bioinformatics analysis pipeline**

We used the cBioPortal online platform to query the TCGA stomach adenocarcinoma (2017, provisional) sequencing dataset (http://www.cbioportal.org/study?id=stad_tcga#summary). A total of 415 tumor samples (from the TCGA database) with messenger RNA (mRNA) next-generation sequencing data were used. Co-expressed genes predicted by cBioPortal online analysis with Pearson correlation coefficient \( \geq 0.4 \) were selected for gene ontology (GO) enrichment annotation using the PANTHER online platform (Ver. 7). Protein interactions were predicted using the STRING online analysis platform (Ver. 10.5) with minimum required interaction score adjusted to 0.15 to obtain the maximal interactions. The acquired protein interaction network was subjected to topological structural analysis using Cytoscape software (Ver. 3.5.1) using the default settings. Genes with a high degree of connection were subjected to transcription factor enrichment prediction using FunRich software (Ver. 3) using the default settings.

**Western blotting**

This research was approved by the ethical board of Henan Tumor Hospital (No. 2018132). Twenty-two gastric cancer patients were enrolled. Informed consent was obtained from each patient. Their clinical-pathological records are summarized in Table 1. Gastric cancer biopsies and non-cancerous adjacent biopsies were obtained from these patients. The tissue samples were analyzed by Western blotting to detect cyclin E and nuclear transcription factor Y subunit.
alpha (NF-YA) protein expression using beta-actin protein as the loading control. Primary antibodies against cyclin E (ab71535), NF-YA (ab23471), beta-actin (ab16039), and correlating secondary antibody (ab205718) were purchased from Abcam Trading Company Ltd. (Cambridge, United Kingdom). Gastric cancer patients were grouped into cyclin E high/low and NF-YA high/low groups based on the gray scale analysis of Western blotting results. Cyclin E or NF-YA expression higher or lower than the average was considered high or low expression, respectively. The NF-YA and cyclin E expression levels in gastric cancer specimens from patients with different TNM stages are presented in Table 2.

Statistical analyses

Statistical analyses were performed using Graphpad Prism (Ver. 7). Patients’ survival was compared by Kaplan–Meier curve analysis (log-rank test) using SPSS software ver. 19.0 (IBM, New York, NY, USA). Student’s t-test was adopted for statistical analysis of Western blotting results. A P-value < 0.05 was considered statistically significant.

Results

Analysis of cyclin E co-expression genes in gastric cancer

To identify genes co-existing with cyclin E and to identify potential oncogenes in gastric cancer, we used cBioPortal online platform to predict cyclin E co-expression genes among all 415 samples within the stomach adenocarcinoma (TCGA provisional) sample set. After filtering the co-expression gene prediction results, 78 predicted genes, including 73 protein coding genes and 5 non-coding genes with Pearson correlation coefficient ≥ 0.4 were selected. Their expressions were considered to be correlated with cyclin E expression. The top 15 protein coding genes with their gene symbols, chromosome locations, Pearson correlation, and Spearman correlation coefficients are summarized and listed in Table 3. To better understand the involvement of these predicted genes in cellular composition and function, we annotated them in the GO database using the PANTHER online classification system (Fig. 1). The annotation results suggested that these genes that were presumably co-expressed with cyclin E participated mostly in mitosis and regulation
of the cell cycle, consistent with the role of cyclin E in proliferation. We next surveyed the interaction (including predicted association) network among the 73 protein coding genes using the STRING analysis platform and further analyzed the topological structure of the predicted interaction network using Cytoscape software (Ver. 3.5.1). Nineteen genes at the central of the predicted interaction network were identified (Fig. 2 and Table 4). The majority have been previously suggested to promote the progression of gastric cancer or have been associated with poor prognosis. Considering the potential co-expression of these 19 genes with cyclin E and their involvement in gastric cancer progression, we performed a transcription factor enrichment prediction using FunRich software (Fig. 3). The enrichment prediction revealed transcription factor NF-YA as the only one significant result ($P < 0.05$). It was the most highly related to the 19 queried genes.

**High expression of cyclin E and NF-YA is associated with gastric cancer progression and poor prognosis**

Based on the previous results, we hypothesized that cyclin E and NF-YA may be related to the promotion of the progression of gastric cancer. As a
proof-of-concept, we examined cyclin E and NF-YA protein expression levels in 22 pairs of gastric cancer specimens and non-cancerous counterparts. Significant up-regulation and co-expression ($P < 0.001$) of cyclin E and NF-YA in gastric cancer were revealed by Western blotting (Fig. 4). The results of Fig. 4A and B showed that cyclin E and NF-YA were highly expressed in gastric cancer tissues compared with adjacent tissues. Fig. 4C showed that high expression of NF-YA tended to be associated with increased cyclin E expression. Analysis of specimen donors’ clinical records also revealed that the high expression of NF-YA tended to be associated with increased cyclin E expression, both of which were associated with the progression of gastric cancer (Table 2). We further compared the survival curves of patients with different cyclin E and NF-YA expression levels based on the Western blotting analysis results by Kaplan–Meier curve analysis (Fig. 5). Gastric cancer patients with high cyclin E or high NF-YA expression level clearly showed relatively low overall survival compared to patients with low cyclin E or NF-YA expression ($P < 0.05$).

Discussion

This study sought to identify genes potentially co-expressed with the cyclin E oncogene in gastric
cancer and to clarify the probable regulatory mechanisms. By querying the public TCGA stomach adenocarcinoma sequencing data, 78 genes were implicated possibly being co-expressed with cyclin E. Pearson correlation coefficient evaluation of the correlation between the co-expression of these genes and cyclin E used a coefficient threshold set at 0.4.\(^{19,20}\) The 78 genes included 5 non-coding genes (\(\text{LOC642852}, \text{PHF2P1}, \text{BAIAP2-AS1}, \text{CSNK1A1P1}, \text{and MIMT1})\).

These non-coding genes and their transcripts (i.e. non-coding RNAs) are important for regulating gene transcription or translation, and their changes in expression level often have a strong influence on phenotype. However, due to their relatively low coefficients (<0.4) and weak correlations with cyclin E, the focus shifted from the non-coding genes to the protein-coding genes with the highest correlation. The top 15 of these genes comprise those implicated in the development of gastric cancer. Jun et al\(^{21}\) reported the association of \(UQCRFS1\) amplification with gastric cancer progression and unfavorable prognosis. Yu et al\(^{22}\) subsequently demonstrated that zinc finger protein 331 may suppress gastric carcinogenesis by down-regulating \(UQCRFS1\) as well as other genes involved in cell cycle promotion. Kaneko et al\(^{23}\) reported that \(NUF2\) (also known as CDCA1) is frequently upregulated in gastric cancer, and targeting this gene by small interfering RNA may induce cell cycle arrest and apoptosis in gastric cancer cells \textit{in vitro}. Similar results have been reported for \(PSRC1\) and \(NEK2).\(^{24–26}\)

GO annotation is a powerful method to help understand cellular participation and function of a set of genes with potential allocations.\(^{27,28}\) GO annotation of the 73 protein coding genes potentially co-expressed with cyclin E showed that these genes were mostly enriched in the promotion of the cell cycle and in mitosis. These results strongly suggest that genes co-expressed with cyclin E may have a similar function in promoting cell proliferation and gastric cancer progression.

![Table 4](image)

| Gene Symbol | Connectivity (Degree) | Pearson Co. | Spearman Co. |
|-------------|-----------------------|-------------|--------------|
| NDC80       | 19                    | 0.44        | 0.55         |
| KIF20A      | 19                    | 0.42        | 0.61         |
| NEK2        | 19                    | 0.49        | 0.64         |
| NUFS2       | 18                    | 0.52        | 0.61         |
| KIF2C       | 18                    | 0.45        | 0.61         |
| TPX2        | 18                    | 0.46        | 0.6          |
| BIRC5       | 17                    | 0.43        | 0.59         |
| KIF4A       | 17                    | 0.41        | 0.62         |
| SPAG5       | 17                    | 0.47        | 0.66         |
| CDC25C      | 16                    | 0.42        | 0.57         |
| KIFC1       | 15                    | 0.42        | 0.56         |
| TRAP1       | 15                    | 0.43        | 0.6          |
| TROAP       | 15                    | 0.4         | 0.59         |
| GTSE1       | 15                    | 0.45        | 0.56         |
| TACC3       | 15                    | 0.45        | 0.48         |
| PSRC1       | 13                    | 0.51        | 0.5          |
| STMN1       | 12                    | 0.4         | 0.43         |
| CENPL       | 9                     | 0.44        | 0.6          |
| TUBA3E      | 6                     | 0.41        | 0.01         |

Pearson Co.: Pearson correlation coefficient; Spearman Co.: Spearman correlation coefficient.

![Fig. 3](image)

**Fig. 3.** Transcription factor enrichment analysis of 19 predicted cyclin E co-expressing genes. Percentage of genes enriched for each transcription factor is plotted on the left axis and \(-\log_{10}P\) on the right axis. The dotted horizontal line represents the \(P = 0.05\) threshold.
We further hypothesized that these genes playing similar roles and with potential correlation might be involved or regulated by the same signal regulatory network, and their transcription might be regulated by some shared transcriptional factors. To reveal the interaction network of proteins coded by the 73 discovered cyclin E co-expressing protein coding genes, we employed the STRING online analysis platform to examine the interactions that were experimentally verified or predicted by an algorithm. We further analyzed the topological structure of the summarized interaction network using Cytoscape software. We discovered 19 genes at the central of the interaction network of the 73 genes based on the topological structure. Genes with a degree of connection exceeding 15, except for SPAG5, have been previously linked to the development of gastric cancer. The result demonstrates the robustness of our bioinformatics analysis methods and reveals a gastric cancer-promoting interaction network associated with cyclin E.

A transcription factor enrichment prediction performed using the FunRich software identified a novel transcription factor, NF-YA, that might be the most significant transcription factor associated with genes in this interaction network that we have discovered. The association of NF-YA with cancer progression has been preliminarily reported in other cancer models. The role of NF-YA seems to mainly involve facilitating the transcription of genes in the cell cycle and cell proliferation. Previously, a role of NF-YA in gastric cancer has not been defined. NF-YA is a subunit of the NF-Y heterotrimer, which has been suggested to aid in transcription regulation.
tumor development by binding to promoter or enhancer regions of related genes. Its impact on gastric cancer development has not been described. Based on the bioinformatics analysis results, we examined the status of NF-YA and cyclin E expression in paired samples of gastric cancer biopsies and non-cancerous counterparts acquired from 22 gastric cancer patients. Our results strongly suggest that NF-YA is an independent prognostic factor for gastric cancer patients. These results suggest that NF-YA might be involved in increasing the expression of cyclin E and in promoting gastric cancer development by increasing the expression of cell proliferation related genes.

The collective findings support the potential relationship between cyclin E overexpression and the transcription factor NF-YA, both of which have strong prognostic value. NF-YA may promote the progression of gastric cancer by increasing the transcription of cyclin E and other cell cycle promoting genes. Targeting NF-YA may be a feasible therapeutic strategy in treating gastric cancer and further studies are warranted.

References

1. Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17:93–115.
2. Patel TN, Roy S, Ravi R. Gastric cancer and related epigenetic alterations. Ecamericalesci. 2017;11:714.
3. Figueiredo C, Camargo MC, Leite M, Fuentes-Panan, Rabkin CS, Machado JC. Pathogenesis of gastric cancer: genetics and molecular classification. Curr Top Microbiol Immunol. 2017;400:277–304.
4. Lazar DC, Tahan S, Cornianu M, Faur A, Goldış A. New advances in targeted gastric cancer treatment. World J Gastroenterol. 2016;22:6776–6799.
5. Berger H, Marques MS, Zietlow R, Meyer TF, Machado JC, Figueiredo C. Gastric cancer pathogenesis. Helicobacter. 2016;21(suppl 1):34–38.
6. Ooi A, Ohmura T, Nakamura R, et al. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. Hum Pathol. 2017;61:58–67.
7. Alsinor M, Landolfi S, Aura C, et al. Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. Ann Oncol. 2015;26:438–439.
8. Huang L, Ren F, Tang R, Feng Z, Chen G. Prognostic value of expression of cyclin E in gastrointestinal cancer: a systematic review and meta-analysis. Technol Cancer Res Treat. 2016;15:12–19.
9. Schrampl P, Bucher C, Bissig H, et al. Cyclin E overexpression and amplification in human tumours. J Pathol. 2003;200:375–382.
10. Liang B, Wang S, Yang X, Ye Y, Yu Y, Cui Z. Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer. Chin Med J (Engl). 2003;116:20–23.
11. Sutter T, Dansranjavan T, Lubinski J, et al. Overexpression of cyclin E protein is closely related to the mutator phenotype of colorectal carcinoma. Int J Colorectal Dis. 2002;17:374–380.
12. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the eBioPortal. Sci Signal. 2013;6:pl1.
13. Cerami E, Gao J, Dogrusoz U, et al. The eBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404.
14. Thomas PD, Campbell MJ, Kejarwali A, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003;13:2129–2141.
15. Mi H, Dong Q, Muruganujan A, Gaudet P, Lewis S, Thomas PD. PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. Nucleic Acids Res. 2010;38:D204–D210.
16. Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447–D452.
17. Killooyne S, Carter GW, Smith J, Boyle J. Cytoescape: a community-based framework for network modeling. Methods Mol Biol. 2009;563:219–239.
18. Pathan M, Keerthikumar S, Ang CS, et al. FunRich: an open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15:2597–2601.
19. Bo L, Wei B, Li C, Wang Z, Gao Z, Miao Z. Identification of potential key genes associated with glioblastoma based on the gene expression profile. Oncol Lett. 2017;14:2045–2052.
20. Couto CMV, Comin CH, Costa LDF. Effects of threshold on the topology of gene co-expression networks. Mol BioSyst. 2017;13:2024–2035.
21. Yu J, Liang QY, Wang J, et al. Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer. Oncogene. 2013;32:307–317.
22. Jun KH, Kim SY, Yoon JH, Song JH, Park WS. Amplification of the UQCRFS1 gene in gastric cancers. J Gastric Cancer. 2012;12:73–80.
23. Kaneko N, Miura K, Gu Z, et al. siRNA-mediated knockdown against CDC15 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis. Biochem Biophys Res Commun. 2009;390:1235–1240.
24. Dan B, Sharma A, Xu H, et al. Transcriptomic changes induced by mycophenolic acid in gastric cancer cells. Am J Transl Res. 2013;6:28–42.
25. Tong H, Wang J, Chen H, Wang Z, Fan H, Ni Z. Transcriptomic analysis of gene expression profiles of stomach carcinoma reveal abnormal expression of mitotic components. Life Sci. 2017;170:41–49.
26. Fang Y, Kong Y, Xi J, et al. Preclinical activity of MBM-5 in gastrointestinal cancer by inhibiting NEK2 kinase activity. Oncotarget. 2016;7:79327–79341.
27. Arnaud MB, Costanzo MC, Shah P, Skrzypek MS, Sherlock G. Gene Ontology and the annotation of pathogen genomes: the cBioPortal. Trends Microbiol. 2009;17:295–303.
28. Thomas PD, Mi H, Lewis S. Ontology annotation: mapping genomic regions to biological function. Curr Opin Chem Biol. 2007;11:4–11.
29. Crosera KTB, Moffa EB, Xiao Y, Siqueira WL. Merging in-silico and in vitro salivary protein complex partners using the STRING database: a tutorial. J Proteomics. 2018;171:87–94.
30. Lubec G, Afjehi-Sadat L, Yang JW, John JP. Searching for hypothetical proteins: theory and practice based upon original data and literature. Prog Neurobiol. 2005;77:90–127.
31. Miryala SK, Anbarasu A, Ramaiah S. Discerning molecular interactions: a comprehensive review on biomolecular interaction databases and network analysis tools. *Gene*. 2018;642:84–94.
32. Suderman M, Hallett M. Tools for visually exploring biological networks. *Bioinformatics*. 2007;23:2651–2659.
33. Bai T, Yokobori T, Altan B, et al. High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients. *Br J Cancer*. 2017;116:1177–1185.
34. Imai T, Oue N, Yamamoto Y, et al. Overexpression of KIFC1 and its association with spheroid formation in esophageal squamous cell carcinoma. *Pathol Res Pract*. 2017;213:1388–1393.
35. Yun M, Rong J, Lin ZR, et al. High expression of transforming acidic coiled coil-containing protein 3 strongly correlates with aggressive characteristics and poor prognosis of gastric cancer. *Oncol Rep*. 2015;34:1397–1405.
36. Subhash VV, Tan SH, Tan WL, et al. GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells. *BMC Cancer*. 2015;15:550.
37. Chen F, Jin X, Zhao J, Gou S. DN604: a platinum(II) drug candidate with classic SAR can induce apoptosis via suppressing CK2-mediated p-cdc25C subcellular localization in cancer cells. *Exp Cell Res*. 2018;364:68–83.
38. Ma H, Yue X, Gao L, et al. ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA. *Oncotarget*. 2015;6:1049–1063.
39. Zhou SJ, Deng YL, Liang HF, Jaoude JC, Liu FY. Hepatitis B virus X protein promotes CREB-mediated activation of miR-3188 and Notch signaling in hepatocellular carcinoma. *Cell Death Differ*. 2017;24:1577–1587.
40. Han L, Zhang EB, Yin DD, et al. Low expression of long non-coding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. *Cell Death Dis*. 2015;6:e1665.
41. Garipov A, Li H, Bitler BG, Thapa RJ, Balachandran S, Zhang R. NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells. *Mol Cancer Res*. 2013;11:360–369.
42. Maity SN. NF-Y (CBF) regulation in specific cell types and mouse models. *Biochim Biophys Acta*. 2017;1860:598–603.
43. Gurtner A, Manni I, Piaggio G. NF-Y in cancer: impact on cell transformation of a gene essential for proliferation. *Biochim Biophys Acta*. 2017;1860:604–616.
44. Dolfini D, Gatta R, Mantovani R. NF-Y and the transcriptional activation of CCAAT promoters. *Crit Rev Biochem Mol Biol*. 2012;47:29–49.

Edited by Pei-Fang Wei